Yonsei Cancer Hospital Proves Excellence in Combination Treatment for EGFR Mutant Lung Cancer
Jul 02, 2024
The combination of the three-generation EGFR mutant lung cancer, which is used as the first-line treatment for lung cancer, has produced better results.
Cho Byung-chul, head of the Center for Lung Cancer at Yonsei Cancer Hospital, said on the 1st that in a multi-national, randomized phase 3 study of EGFR-mutated lung cancer patients, the combination therapy of amivantamab and lasertinib increases the progression-free survival period by 30% compared to osimertinib, a standard treatment.
The results of the study were published in the international journal 『New England Journal of Medicine』 (IF 176.082). Professor Cho Byung-chul is the first in Korea to publish NEJM No. 2 as an author in the field of oncology. It is also the first time that clinical results of domestic anticancer drugs have been published in NEJM.
EGFR-mutated lung cancer accounts for 25% to 40% of all lung cancers and is the largest subtype of lung cancer, with 450,000 new cases occurring every year worldwide. Osimertinib is the only drug that has been approved by the U.S. FDA as a first-line treatment. Osimertinib has a response rate of 80% and a progression-free survival period of 16 to 18 months, and most of the patients are resistant thereafter.
Professor Cho Byung-chul confirmed the effectiveness and safety of amivantamab and lasertinib combination therapy. Amivantamab and lasertinib are approved by the Ministry of Food and Drug Safety as drugs for advanced EGFR mutant lung cancer and EGFR exon20 mutant lung cancer, respectively. As the effects of combination therapy were confirmed in previous Phase 1 and Phase 2 studies, multinational, randomized phase 3 clinical trials were continued.
Progression-free survival and response duration of 429 patients treated with combination therapy were 23.7 months and 25.8 months, which was longer than 429 patients treated with osimertinib (16.6 months and 16.8 months). The two-year survival rate was also 74% in the combined group, higher than 69% in the osimertinib group.
The main side effects of combination therapy were mostly adjustable due to skin rash and inflammation around nails.
Cho Byung-chul, director of the Center, who has led from amivantamab, lasertinib-mediated research to phase 3 research, and phase 3 clinical trials with both drugs, confirmed superior therapeutic effects than conventional treatments with amivantamab and lasertinib combination"As a result of this clinical trial, combination therapy has been selected by the FDA as a priority subject for review" he said.
Cho Byung-chul, head of the Center for Lung Cancer at Yonsei Cancer Hospital, said on the 1st that in a multi-national, randomized phase 3 study of EGFR-mutated lung cancer patients, the combination therapy of amivantamab and lasertinib increases the progression-free survival period by 30% compared to osimertinib, a standard treatment.
The results of the study were published in the international journal 『New England Journal of Medicine』 (IF 176.082). Professor Cho Byung-chul is the first in Korea to publish NEJM No. 2 as an author in the field of oncology. It is also the first time that clinical results of domestic anticancer drugs have been published in NEJM.
EGFR-mutated lung cancer accounts for 25% to 40% of all lung cancers and is the largest subtype of lung cancer, with 450,000 new cases occurring every year worldwide. Osimertinib is the only drug that has been approved by the U.S. FDA as a first-line treatment. Osimertinib has a response rate of 80% and a progression-free survival period of 16 to 18 months, and most of the patients are resistant thereafter.
Professor Cho Byung-chul confirmed the effectiveness and safety of amivantamab and lasertinib combination therapy. Amivantamab and lasertinib are approved by the Ministry of Food and Drug Safety as drugs for advanced EGFR mutant lung cancer and EGFR exon20 mutant lung cancer, respectively. As the effects of combination therapy were confirmed in previous Phase 1 and Phase 2 studies, multinational, randomized phase 3 clinical trials were continued.
Progression-free survival and response duration of 429 patients treated with combination therapy were 23.7 months and 25.8 months, which was longer than 429 patients treated with osimertinib (16.6 months and 16.8 months). The two-year survival rate was also 74% in the combined group, higher than 69% in the osimertinib group.
The main side effects of combination therapy were mostly adjustable due to skin rash and inflammation around nails.
Cho Byung-chul, director of the Center, who has led from amivantamab, lasertinib-mediated research to phase 3 research, and phase 3 clinical trials with both drugs, confirmed superior therapeutic effects than conventional treatments with amivantamab and lasertinib combination"As a result of this clinical trial, combination therapy has been selected by the FDA as a priority subject for review" he said.
|
bellho@sportschosun.com
